Lymph nodes-The neglected battlefield in tuberculosis.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
08 2020
Historique:
entrez: 14 8 2020
pubmed: 14 8 2020
medline: 23 9 2020
Statut: epublish

Résumé

Lymph nodes, particularly thoracic lymph nodes, are among the most common sites of extrapulmonary tuberculosis (TB). However, Mycobacterium tuberculosis (Mtb) infection in these organs is understudied. Aside from being sites of initiation of the adaptive immune system, lymph nodes also serve as niches of Mtb growth and persistence. Mtb infection results in granuloma formation that disrupts and-if it becomes large enough-replaces the normal architecture of the lymph node that is vital to its function. In preclinical models, successful TB vaccines appear to prevent spread of Mtb from the lungs to the lymph nodes. Reactivation of latent TB can start in the lymph nodes resulting in dissemination of the bacteria to the lungs and other organs. Involvement of the lymph nodes may improve Bacille Calmette-Guerin (BCG) vaccine efficacy. Lastly, drug penetration to the lymph nodes is poor compared to blood, lung tissue, and lung granulomas. Future studies on evaluating the efficacy of vaccines and anti-TB drug treatments should include consideration of the effects on thoracic lymph nodes and not just the lungs.

Identifiants

pubmed: 32790739
doi: 10.1371/journal.ppat.1008632
pii: PPATHOGENS-D-20-00662
pmc: PMC7425845
doi:

Substances chimiques

Tuberculosis Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008632

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Acta Tuberc Scand. 1950;24(3-4):311-46
pubmed: 14783027
Infect Immun. 2004 Oct;72(10):5963-71
pubmed: 15385500
Int J Tuberc Lung Dis. 2004 Apr;8(4):392-402
pubmed: 15141729
Nat Rev Immunol. 2017 Nov;17(11):691-702
pubmed: 28736436
J Immunol. 2020 Feb 1;204(3):644-659
pubmed: 31862711
Probl Tuberk. 1985;(4):55-7
pubmed: 4001111
Toxicol Pathol. 2006;34(5):409-24
pubmed: 17067937
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10961-6
pubmed: 18667699
Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71
pubmed: 25184558
J Immunol. 2017 Jul 15;199(2):806-815
pubmed: 28592427
J Vis Exp. 2017 Sep 5;(127):
pubmed: 28930979
Infect Immun. 2014 Jun;82(6):2400-4
pubmed: 24664509
Nature. 2007 Nov 1;450(7166):110-4
pubmed: 17934446
Front Immunol. 2019 Mar 21;10:532
pubmed: 30949177
PLoS Pathog. 2016 Jul 05;12(7):e1005739
pubmed: 27379816
Curr Clin Pharmacol. 2010 May;5(2):96-114
pubmed: 20156156
JAMA. 1965 Dec 6;194(10):1086-92
pubmed: 5294688
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Sci Transl Med. 2014 Dec 3;6(265):265ra167
pubmed: 25473035
Antimicrob Agents Chemother. 2013 Sep;57(9):4237-4244
pubmed: 23796926
Nat Med. 2016 Oct;22(10):1090-1093
pubmed: 27595321
Clin Infect Dis. 2011 Sep;53(6):555-62
pubmed: 21865192
Annu Rev Immunol. 2013;31:475-527
pubmed: 23516984
Vaccine. 2013 Feb 4;31(7):1057-64
pubmed: 23273509
Tuberculosis (Edinb). 2016 Jan;96:1-12
pubmed: 26786648
J Assoc Physicians India. 2009 Aug;57:585-90
pubmed: 20209720
Sci Rep. 2015 Oct 15;5:15214
pubmed: 26469538
Tuberculosis (Edinb). 2001;81(1-2):79-86
pubmed: 11463227
Front Pediatr. 2019 Aug 27;7:350
pubmed: 31508399
Nat Med. 2018 Feb;24(2):130-143
pubmed: 29334373
Infect Immun. 2004 Mar;72(3):1700-5
pubmed: 14977978
Microbiol Spectr. 2016 Dec;4(6):
pubmed: 28084205
Infect Immun. 2009 Feb;77(2):598-603
pubmed: 19064634
Nat Med. 2014 Jan;20(1):75-9
pubmed: 24336248
Acta Tuberc Scand. 1957;33(1-2):37-92; concl
pubmed: 13424392
Nat Med. 1996 Apr;2(4):430-6
pubmed: 8597953
Infect Immun. 2003 Oct;71(10):5831-44
pubmed: 14500505
J Immunol. 2007 Aug 15;179(4):2532-41
pubmed: 17675515
Respir Med. 2006 Nov;100(11):1862-70
pubmed: 16949809
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
Nat Commun. 2015 Oct 13;6:8533
pubmed: 26460802
PLoS Pathog. 2011 Nov;7(11):e1002345
pubmed: 22072965
mBio. 2017 May 9;8(3):
pubmed: 28487426
Infect Immun. 2006 Sep;74(9):5397-401
pubmed: 16926435
J Immunol. 2013 May 1;190(9):4707-16
pubmed: 23547119
J Vet Diagn Invest. 1996 Jul;8(3):351-4
pubmed: 8844579
J Glob Infect Dis. 2013 Apr;5(2):54-9
pubmed: 23853432
Cell Host Microbe. 2016 Mar 9;19(3):275-6
pubmed: 26962938
PLoS Pathog. 2015 Jan 22;11(1):e1004603
pubmed: 25611466
PLoS One. 2010 Mar 10;5(3):e9611
pubmed: 20224771
J Thorac Dis. 2018 Jun;10(6):3609-3621
pubmed: 30069358
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
PLoS One. 2009;4(1):e4204
pubmed: 19145246
Tuberculosis (Edinb). 2006 Sep;86(5):386-94
pubmed: 16473044
AIDS Res Hum Retroviruses. 2012 Dec;28(12):1693-702
pubmed: 22480184
Infect Immun. 2009 Oct;77(10):4631-42
pubmed: 19620341
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12
pubmed: 24469825
Infect Immun. 1996 Nov;64(11):4776-87
pubmed: 8890239
J Infect Dev Ctries. 2012 Jan 12;6(1):6-12
pubmed: 22240421
Tuberculosis (Edinb). 2014 Dec;94(6):634-43
pubmed: 25224753
Microbes Infect. 2008 Jun;10(7):711-5
pubmed: 18538612
Infect Immun. 2018 Jan 22;86(2):
pubmed: 28947646
Nat Immunol. 2008 Feb;9(2):155-65
pubmed: 18193049
Arthritis Rheum. 2010 Feb;62(2):340-50
pubmed: 20112395
J Exp Med. 2003 Sep 1;198(5):715-24
pubmed: 12953093
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14188-93
pubmed: 22826237
Am J Trop Med Hyg. 2019 Jun;100(6):1401-1406
pubmed: 30994092
Infect Immun. 2002 Aug;70(8):4501-9
pubmed: 12117962
Nature. 2016 Feb 4;530(7588):51-56
pubmed: 26814962
Immunol Rev. 2015 Mar;264(1):60-73
pubmed: 25703552
J Immunol. 2007 Aug 15;179(4):2509-19
pubmed: 17675513
Front Cell Infect Microbiol. 2013 Jun 21;3:21
pubmed: 23802100
Cold Spring Harb Perspect Med. 2014 Sep 11;4(12):a018564
pubmed: 25213189
PLoS Pathog. 2018 Oct 12;14(10):e1007305
pubmed: 30312351
Immunity. 2009 Aug 21;31(2):342-55
pubmed: 19699173
Clin Infect Dis. 2009 Nov 1;49(9):1350-7
pubmed: 19793000
Infect Immun. 2006 Jul;74(7):3790-803
pubmed: 16790751
Front Immunol. 2019 Nov 01;10:2479
pubmed: 31736945
Am J Pathol. 2009 Jun;174(6):2211-24
pubmed: 19435796
PLoS Pathog. 2020 Jul 30;16(7):e1008413
pubmed: 32730321
Proc R Soc Med. 1932 Mar;25(5):725-33
pubmed: 19988654
J Infect Dis. 2004 Dec 15;190(12):2137-45
pubmed: 15551212
Tubercle. 1948 Nov;29(11):245-51
pubmed: 18101320
J Exp Med. 2008 Jan 21;205(1):105-15
pubmed: 18158321
Indian J Pediatr. 2000 Feb;67(2 Suppl):S28-33
pubmed: 11129904
J Comput Biol. 2020 Jan;27(1):121-130
pubmed: 31460784
PLoS Pathog. 2018 Nov 1;14(11):e1007337
pubmed: 30383808
Lancet Infect Dis. 2014 Mar;14(3):250-5
pubmed: 24268591

Auteurs

Sharie Keanne C Ganchua (SKC)

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.

Alexander G White (AG)

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.

Edwin C Klein (EC)

Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.

JoAnne L Flynn (JL)

Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH